Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
- PMID: 29526139
- DOI: 10.1056/NEJMoa1800866
Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
Abstract
Background: In an early analysis of this trial, use of a magnetically levitated centrifugal continuous-flow circulatory pump was found to improve clinical outcomes, as compared with a mechanical-bearing axial continuous-flow pump, at 6 months in patients with advanced heart failure.
Methods: In a randomized noninferiority and superiority trial, we compared the centrifugal-flow pump with the axial-flow pump in patients with advanced heart failure, irrespective of the intended goal of support (bridge to transplantation or destination therapy). The composite primary end point was survival at 2 years free of disabling stroke (with disabling stroke indicated by a modified Rankin score of >3; scores range from 0 to 6, with higher scores indicating more severe disability) or survival free of reoperation to replace or remove a malfunctioning device. The noninferiority margin for the risk difference (centrifugal-flow pump group minus axial-flow pump group) was -10 percentage points.
Results: Of 366 patients, 190 were assigned to the centrifugal-flow pump group and 176 to the axial-flow pump group. In the intention-to-treat population, the primary end point occurred in 151 patients (79.5%) in the centrifugal-flow pump group, as compared with 106 (60.2%) in the axial-flow pump group (absolute difference, 19.2 percentage points; 95% lower confidence boundary, 9.8 percentage points [P<0.001 for noninferiority]; hazard ratio, 0.46; 95% confidence interval [CI], 0.31 to 0.69 [P<0.001 for superiority]). Reoperation for pump malfunction was less frequent in the centrifugal-flow pump group than in the axial-flow pump group (3 patients [1.6%] vs. 30 patients [17.0%]; hazard ratio, 0.08; 95% CI, 0.03 to 0.27; P<0.001). The rates of death and disabling stroke were similar in the two groups, but the overall rate of stroke was lower in the centrifugal-flow pump group than in the axial-flow pump group (10.1% vs. 19.2%; hazard ratio, 0.47; 95% CI, 0.27 to 0.84, P=0.02).
Conclusions: In patients with advanced heart failure, a fully magnetically levitated centrifugal-flow pump was superior to a mechanical-bearing axial-flow pump with regard to survival free of disabling stroke or reoperation to replace or remove a malfunctioning device. (Funded by Abbott; MOMENTUM 3 ClinicalTrials.gov number, NCT02224755 .).
Comment in
-
A New Left Ventricular Assist Device - Better, but Still Not Ideal.N Engl J Med. 2018 Apr 12;378(15):1442-1443. doi: 10.1056/NEJMe1802639. N Engl J Med. 2018. PMID: 29641957 No abstract available.
-
The HeartMate 3 pump: Overcoming the hemocompatibility gap.J Thorac Cardiovasc Surg. 2018 Dec;156(6):2140-2142. doi: 10.1016/j.jtcvs.2018.05.055. Epub 2018 Jun 4. J Thorac Cardiovasc Surg. 2018. PMID: 30041926 No abstract available.
-
Magnetically Levitated Cardiac Pump at 2 Years.N Engl J Med. 2018 Aug 30;379(9):896-7. doi: 10.1056/NEJMc1809738. N Engl J Med. 2018. PMID: 30179390 No abstract available.
Similar articles
-
A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure.N Engl J Med. 2017 Feb 2;376(5):440-450. doi: 10.1056/NEJMoa1610426. Epub 2016 Nov 16. N Engl J Med. 2017. PMID: 27959709 Clinical Trial.
-
A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report.N Engl J Med. 2019 Apr 25;380(17):1618-1627. doi: 10.1056/NEJMoa1900486. Epub 2019 Mar 17. N Engl J Med. 2019. PMID: 30883052 Clinical Trial.
-
Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial.JAMA. 2022 Sep 27;328(12):1233-1242. doi: 10.1001/jama.2022.16197. JAMA. 2022. PMID: 36074476 Free PMC article. Clinical Trial.
-
Evolving trends in mechanical circulatory support: Clinical development of a fully magnetically levitated durable ventricular assist device.Trends Cardiovasc Med. 2020 May;30(4):223-229. doi: 10.1016/j.tcm.2019.05.013. Epub 2019 Jun 4. Trends Cardiovasc Med. 2020. PMID: 31201005 Review.
-
Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol.J Heart Lung Transplant. 2016 Apr;35(4):528-36. doi: 10.1016/j.healun.2016.01.021. Epub 2016 Jan 30. J Heart Lung Transplant. 2016. PMID: 27044532 Review.
Cited by
-
Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review.Heart Fail Rev. 2024 Nov 8. doi: 10.1007/s10741-024-10465-z. Online ahead of print. Heart Fail Rev. 2024. PMID: 39514145 Review.
-
Different ECLS Pump Configurations for Temporary Right Ventricular Assist Device in LVAD Patients: A Retrospective Case-Control Study.Life (Basel). 2024 Oct 7;14(10):1274. doi: 10.3390/life14101274. Life (Basel). 2024. PMID: 39459574 Free PMC article.
-
Platelet reactivity is associated with pump thrombosis in patients with left ventricular assist devices.Res Pract Thromb Haemost. 2024 Sep 5;8(6):102564. doi: 10.1016/j.rpth.2024.102564. eCollection 2024 Aug. Res Pract Thromb Haemost. 2024. PMID: 39391561 Free PMC article.
-
Durable left ventricular assist devices in pediatrics: impact of body size on outcomes and size limitations.J Artif Organs. 2024 Sep 6. doi: 10.1007/s10047-024-01467-7. Online ahead of print. J Artif Organs. 2024. PMID: 39240401 Review.
-
Hemolysis Index Correlations with Plasma-Free Hemoglobin and Plasma Lactate Dehydrogenase in Critically Ill Patients under Extracorporeal Membrane Oxygenation or Mechanical Circulatory Support-A Single-Center Study.Diagnostics (Basel). 2024 Mar 23;14(7):680. doi: 10.3390/diagnostics14070680. Diagnostics (Basel). 2024. PMID: 38611592 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical